Table 1.
Baseline (first assessment) characteristics of the study women.
| Number | Incident fracture during the follow-up | P value | ||
|---|---|---|---|---|
| No (n = 2,606) | Yes (n = 266) | |||
| Age (years), mean (standard deviation (sd)) | 2,872 | 66.8 (8.8) | 67.3 (9.2) | 0.36 |
| Body mass index (kg/m2), mean (sd) | 2,615 | 25.9 (5.3) | 26.0 (5.1) | 0.77 |
| Private health insurance, n (%) | 2,843 | 2,480 (96.1) | 251 (95.8) | 0.82 |
| Tertiary education, n (%) | 2,827 | 1,202 (46.8) | 126 (49.0) | 0.49 |
| Prior year weight loss (≥5 kgs), n (%) | 2,839 | 169 (6.6) | 17 (6.5) | 0.99 |
| Current smoking, n (%) | 2,855 | 117 (4.5) | 21 (7.9) | 0.01 |
| Alcohol drinking (≥7 drinks/week), n (%) | 2,858 | 884 (34.1) | 95 (36.1) | 0.50 |
| Prior fracture after 45 years, n (%) | 2,834 | 604 (23.5) | 97 (37.5) | <0.001 |
| Prior fracture after 45 years and being on treatment, n (%)# | 2,807 | 259 (10.0) | 46 (18.1) | <0.001 |
| Any comorbidity∧, n (%) | 2,808 | 1,548 (60.7) | 179 (69.9) | 0.004 |
| Number of falls in the prior year, n (%) | 2,852 | 0.04 | ||
| 0 | 1,633 (63.1) | 148 (56.1) | ||
| 1 | 631 (24.4) | 71 (26.9) | ||
| 2 | 324 (12.5) | 45 (17.1) | ||
#Prior fracture after the age of 45 years and being on treatment for osteoporosis at baseline (first assessment). Treatment was defined as self-reported use of antiosteoporosis medications (i.e., oestrogen, selective oestrogen receptor modulators, bisphosphonates, calcitonin, parathyroid hormone, and strontium).
∧Ever diagnosed with asthma, chronic bronchitis/emphysema, osteoarthritis/degenerative joint disease, rheumatoid arthritis, high cholesterol, hypertension, or osteoporosis.